ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,682.40
0.70%
S&P ASX All Technology
3,019.20
0.10%
Brent Oil
83.395
0.32%
US Dollar vs AUD
1.50807
-0.32%
Bitcoin
64,016.71
0.03%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. TransCode Therapeutics Inc (RNAZ)

  7. TransCode Therapeutics Inc (RNAZ) News

RNAZ TransCode Therapeutics Inc

0.839
0.019 (2.32%)
Pre Market
Last Updated: 22:11:11
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
TransCode Therapeutics Inc RNAZ NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.019 2.32% 0.839 22:11:11
Open Price Low Price High Price Close Price Previous Close
0.82
more quote information »

Recent News

Date Time Source Heading
15/4/202423:00GLOBETransCode Therapeutics Announces FDA Clearance To Initiate..
04/4/202400:10GLOBETransCode Therapeutics Reports 2023 Results; Provides..
28/3/202423:30GLOBETransCode Therapeutics Announces Appointment of Daniel..
12/3/202400:00GLOBETransCode Therapeutics and Akribion Genomics Report Progress..
07/3/202408:15GLOBETransCode Therapeutics To Present At 2024 RNA Leaders Europe..
21/2/202400:00GLOBETransCode Therapeutics Reports Publication of United States..
16/2/202408:00EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202412:12EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
01/2/202408:33EDGAR2Form 8-K - Current report
01/2/202408:05GLOBENasdaq Determines TransCode Therapeutics Compliance with..
30/1/202400:30GLOBETransCode Therapeutics and Debiopharm Announce Collaboration..
23/1/202408:45EDGAR2Form 8-K - Current report
23/1/202408:45GLOBETransCode Therapeutics Announces Closing of $7.25 Million..
20/1/202413:57EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
19/1/202416:15EDGAR2Form EFFECT - Notice of Effectiveness
19/1/202405:27GLOBETransCode Therapeutics Announces Pricing of $7.25 Million..
19/1/202402:39EDGAR2Form S-1/A - General form for registration of securities..
17/1/202423:06EDGAR2Form S-1/A - General form for registration of securities..
17/1/202408:01EDGAR2Form 8-K - Current report
13/1/202408:05GLOBETransCode Therapeutics Reports Further Restructuring to..
12/1/202400:22EDGAR2Form S-1 - General form for registration of securities under..
12/1/202400:00GLOBETransCode Therapeutics Announces 1-for-40 Reverse Stock..
09/1/202408:01EDGAR2Form 8-K - Current report
05/1/202404:41EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
05/1/202400:05GLOBETransCode Therapeutics Publishes Open Letter Outlining..
19/12/202308:28EDGAR2Form DEF 14A - Other definitive proxy statements
13/12/202300:30GLOBETransCode Therapeutics Reports Positive Pre-Clinical Results..
09/12/202308:57EDGAR2Form PRE 14A - Other preliminary proxy statements
09/12/202308:56EDGAR2Form 8-K - Current report
08/12/202308:30EDGAR2Form SC 13G - Statement of acquisition of beneficial..
06/12/202301:00GLOBETransCode Therapeutics To Present Phase 0 Data at 2023 San..
05/12/202309:07EDGAR2Form 8-K - Current report
05/12/202308:10GLOBETransCode Therapeutics Announces Closing of $1.2 Million..
02/12/202309:23EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
01/12/202306:53GLOBETransCode Therapeutics Announces $1.2 Million Registered..
15/11/202308:40EDGAR2Form 8-K - Current report
15/11/202308:30GLOBETransCode Therapeutics Reports Third Quarter 2023 Results;..
10/11/202308:13EDGAR2Form 8-K - Current report
01/11/202313:20APSBiotech Shares Bid Up Following Public Offering Cancellation
31/10/202307:33GLOBETransCode Therapeutics Withdraws Public Offering
28/10/202307:06EDGAR2Form 8-K - Current report
27/10/202323:00GLOBENasdaq Panel Grants TransCode Therapeutics Extension for..
27/10/202307:29EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
27/10/202307:19GLOBETransCode Therapeutics Announces Public Offering of Common..
26/10/202323:00GLOBETransCode Therapeutics Announces Prolonged Survival in..
24/10/202323:05EDGAR2Form 8-K - Current report
24/10/202323:00GLOBETransCode Therapeutics Announces Preliminary Clinical..
16/10/202323:00GLOBETransCode Therapeutics Reports Successful Treatment of..
11/10/202307:00EDGAR2Form SC 13D/A - General statement of acquisition of..
03/10/202307:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Your Recent History

NASDAQ
RNAZ
TransCode Therapeutics
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved